Stimulus-sensitive burst-spiking in burst-suppression in children: implications for management of refractory status

Bernard Dan1, Stewart G Boyd

  • 1Department of Neurology, Hôpital Universitaire des Enfants Reine Fabiola, Free University of Brussels (ULB), Belgium. bernard.dan@ulb.ac.be

Insights

Refractory status epilepticus in children can develop stimulus sensitivity, causing myoclonic jerks and EEG spikes. Halogenated agents effectively treated this rare complication, with outcomes potentially better than in adults.

Area of Science:

  • Pediatric Neurology
  • Clinical Neurophysiology

Background:

  • Refractory status epilepticus (RSE) is a critical condition in children.
  • RSE poses significant management challenges, often requiring intensive care.

Purpose of the Study:

  • To describe a novel phenomenon of stimulus sensitivity in children with RSE.
  • To investigate the clinical and electroencephalogram (EEG) features of this sensitivity.
  • To evaluate treatment strategies and outcomes.

Main Methods:

  • Retrospective review of six pediatric patients with RSE requiring intensive care.
  • Clinical and EEG data analysis, including response to sensory stimulation.
  • Assessment of antiepileptic drug efficacy.

Main Results:

  • Stimulus sensitivity, characterized by myoclonic jerks and EEG burst-spiking, emerged after 24 hours of RSE treatment.
  • Sensitivity was induced by tactile, auditory, and visual stimuli.
  • Standard antiepileptic drugs were ineffective, but halogenated agents abolished the sensitivity.
  • Two of six children died; the rest recovered to their baseline state.

Conclusions:

  • Stimulus sensitivity can develop in pediatric RSE treated with high-dose barbiturates.
  • This sensitivity may be reversible with halogenated agents.
  • Outcomes in children might be more favorable than in adults with similar conditions.
  • Sensory stimulation should be part of the electroclinical assessment in ventilated children with RSE.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...